top of page

International Pharmaceutical Aerosol Consortium on Regulation & Science

The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDPs) by collecting and analyzing data, and conducting joint research and development projects. Representing the OINDP industry since 2000, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals, webinars, and discussions with regulatory bodies.
IPAC-RS Roundtable Webinar Series 2023

In 2021, IPAC-RS launched a new webinar series.  Presented by SMEs in the pharmaceutical sciences, this opportunity enabled attendees to learn about the latest research and regulatory trends.  See the IPAC-RS Roundtables webpage for links to presentations and recordings for the 5 webinars held in 2021 and the 2 webinars held in 2022.


IPAC-RS is continuing its Roundtable series in 2023, supplementing the podium presentations held at the IPAC-RS/RDD Joint session that addressed Regulatory, Science and Technology Innovations Enabling Novel and Improved OINDP Design, Development and Manufacturing.

  • The first webinar of 2023, Advancing Sustainability of Device and Container Closure Systems (Part II) was held on Tuesday, February 7, 2023.  Visit the Roundtable webpage for PDFs of presentation and link to recording. 


Upcoming IPAC-RS Roundtable topics include:

  • Advancing Sustainability of Device and Container Closure Systems (Part III) 

  • Sustainability - Alternate Propellants​

  • Advanced Data Analytics​

  • Regulatory Evolution

Respiratory Drug Delivery and IPAC-RS collaborated again and held a jointly organized session at RDD2022 that addressed Regulatory, Science and Technology Innovations Enabling Novel and Improved OINDP Design, Development and Manufacturing. The podium presentations will be supplemented with subsequent in-depth roundtables (see above for details).

The session moderated by Jennifer Wylie (Merck) and Vijay Sethuraman (Genentech) included:

  • Patient Centric Design:  Paul Upham (Genentech)

  • Sustainability:  Richard Henderson (GlaxoSmithKline)

  • Regulatory Evolution:  Prasad Peri (Teva)

  • Advanced Data Analytics:  Will Ganley (Nanopharm)


News and Events

April 2023

IPAC-RS Survey - Stakholder Perspectives on Switching Current pMDIs to New Propellants 

IPAC-RS invites all interested stakeholders to participate in a survey on Stakeholder Perspectives on Switching Current pMDIs to New Propellants.  


This survey is aimed at understanding the perspectives of industry, regulators, and other stakeholders regarding the forthcoming switch to new propellants.  The output of this survey will be used to inform further actions, such as a Workshop where stakeholders' concerns and potential solutions can be discussed.

Please respond to the survey  by Tuesday, June 13, 2023.

Click here to access the survey.



April 2023

IPAC-RS and ISAM are co-hosting an in-person workshop entitled “
Addressing CMC Questions for Development of Inhaled/Intranasal Biologic Products” at the ISAM Congress on Saturday, April 26, 2023 in Saarbrücken, Germany.   Come to learn about latest updates and join the discussion!  

April 2023

We encourage you to take a look at the IPAC-RS 2022 Year in Review!  
The report highlights the impressive work IPAC-RS accomplished in 2022.  

YIR 2022 cover.JPG

Become an IPAC-RS member today!

Inquire below.

Thanks for submitting!

bottom of page